Cholangiocarcinoma Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

• News
• Research
• Blogs
• Podcasts
• Video
• Funding
• Clinical Trials
• Forums

Ivosidenib, Nivolumab, and Ipilimumab Combination in Previously Treated Subjects With Nonresectable or Metastatic IDH1 Mutant Cholangiocarcinoma
Condition:   IDH1-mutant Cholangiocarcinoma Interventions:   Drug: Ivosidenib;   Drug: Recommended Combination Dose (RCD) of ivosidenib;   Drug: Nivolumab;   Drug: Ipilimumab Sponsors:   Servier Bio-Innovation LLC;   Institut de Recherches Internationales Servier Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 27, 2023 Category: Research Source Type: clinical trials

Senior Adult Hepatobiliary Prehab Study
Conditions:   Hepatobiliary Cancer;   Cholangiocarcinoma;   Liver Metastases Interventions:   Behavioral: Resistance Training;   Behavioral: Aerobic Training Sponsor:   H. Lee Moffitt Cancer Center and Research Institute Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 27, 2023 Category: Research Source Type: clinical trials

Ivosidenib, Nivolumab, and Ipilimumab Combination in Previously Treated Subjects With Nonresectable or Metastatic IDH1 Mutant Cholangiocarcinoma
Condition:   IDH1-mutant Cholangiocarcinoma Interventions:   Drug: Ivosidenib;   Drug: Recommended Combination Dose (RCD) of ivosidenib;   Drug: Nivolumab;   Drug: Ipilimumab Sponsors:   Servier Bio-Innovation LLC;   Institut de Recherches Internationales Servier Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 27, 2023 Category: Research Source Type: clinical trials

Senior Adult Hepatobiliary Prehab Study
Conditions:   Hepatobiliary Cancer;   Cholangiocarcinoma;   Liver Metastases Interventions:   Behavioral: Resistance Training;   Behavioral: Aerobic Training Sponsor:   H. Lee Moffitt Cancer Center and Research Institute Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 27, 2023 Category: Research Source Type: clinical trials

Ivosidenib, Nivolumab, and Ipilimumab Combination in Previously Treated Subjects With Nonresectable or Metastatic IDH1 Mutant Cholangiocarcinoma
Condition:   IDH1-mutant Cholangiocarcinoma Interventions:   Drug: Ivosidenib;   Drug: Recommended Combination Dose (RCD) of ivosidenib;   Drug: Nivolumab;   Drug: Ipilimumab Sponsors:   Servier Bio-Innovation LLC;   Institut de Recherches Internationales Servier Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 27, 2023 Category: Research Source Type: clinical trials

Senior Adult Hepatobiliary Prehab Study
Conditions:   Hepatobiliary Cancer;   Cholangiocarcinoma;   Liver Metastases Interventions:   Behavioral: Resistance Training;   Behavioral: Aerobic Training Sponsor:   H. Lee Moffitt Cancer Center and Research Institute Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 27, 2023 Category: Research Source Type: clinical trials

Ivosidenib, Nivolumab, and Ipilimumab Combination in Previously Treated Subjects With Nonresectable or Metastatic IDH1 Mutant Cholangiocarcinoma
Condition:   IDH1-mutant Cholangiocarcinoma Interventions:   Drug: Ivosidenib;   Drug: Recommended Combination Dose (RCD) of ivosidenib;   Drug: Nivolumab;   Drug: Ipilimumab Sponsors:   Servier Bio-Innovation LLC;   Institut de Recherches Internationales Servier Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 27, 2023 Category: Research Source Type: clinical trials

Senior Adult Hepatobiliary Prehab Study
Conditions:   Hepatobiliary Cancer;   Cholangiocarcinoma;   Liver Metastases Interventions:   Behavioral: Resistance Training;   Behavioral: Aerobic Training Sponsor:   H. Lee Moffitt Cancer Center and Research Institute Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 27, 2023 Category: Research Source Type: clinical trials

Ivosidenib, Nivolumab, and Ipilimumab Combination in Previously Treated Subjects With Nonresectable or Metastatic IDH1 Mutant Cholangiocarcinoma
Condition:   IDH1-mutant Cholangiocarcinoma Interventions:   Drug: Ivosidenib;   Drug: Recommended Combination Dose (RCD) of ivosidenib;   Drug: Nivolumab;   Drug: Ipilimumab Sponsors:   Servier Bio-Innovation LLC;   Institut de Recherches Internationales Servier Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 27, 2023 Category: Research Source Type: clinical trials

Senior Adult Hepatobiliary Prehab Study
Conditions:   Hepatobiliary Cancer;   Cholangiocarcinoma;   Liver Metastases Interventions:   Behavioral: Resistance Training;   Behavioral: Aerobic Training Sponsor:   H. Lee Moffitt Cancer Center and Research Institute Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 27, 2023 Category: Research Source Type: clinical trials

Ivosidenib, Nivolumab, and Ipilimumab Combination in Previously Treated Subjects With Nonresectable or Metastatic IDH1 Mutant Cholangiocarcinoma
Condition:   IDH1-mutant Cholangiocarcinoma Interventions:   Drug: Ivosidenib;   Drug: Recommended Combination Dose (RCD) of ivosidenib;   Drug: Nivolumab;   Drug: Ipilimumab Sponsors:   Servier Bio-Innovation LLC;   Institut de Recherches Internationales Servier Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 27, 2023 Category: Research Source Type: clinical trials

Senior Adult Hepatobiliary Prehab Study
Conditions:   Hepatobiliary Cancer;   Cholangiocarcinoma;   Liver Metastases Interventions:   Behavioral: Resistance Training;   Behavioral: Aerobic Training Sponsor:   H. Lee Moffitt Cancer Center and Research Institute Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 27, 2023 Category: Research Source Type: clinical trials

Ivosidenib, Nivolumab, and Ipilimumab Combination in Previously Treated Subjects With Nonresectable or Metastatic IDH1 Mutant Cholangiocarcinoma
Condition:   IDH1-mutant Cholangiocarcinoma Interventions:   Drug: Ivosidenib;   Drug: Recommended Combination Dose (RCD) of ivosidenib;   Drug: Nivolumab;   Drug: Ipilimumab Sponsors:   Servier Bio-Innovation LLC;   Institut de Recherches Internationales Servier Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 27, 2023 Category: Research Source Type: clinical trials

Senior Adult Hepatobiliary Prehab Study
Conditions:   Hepatobiliary Cancer;   Cholangiocarcinoma;   Liver Metastases Interventions:   Behavioral: Resistance Training;   Behavioral: Aerobic Training Sponsor:   H. Lee Moffitt Cancer Center and Research Institute Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 27, 2023 Category: Research Source Type: clinical trials